title: Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production.
abstract: BACKGROUND
  Zileuton, a 5-lipoxygenase inhibitor, reduces the number of inflammatory lesions in moderate acne and inhibits the synthesis of sebaceous lipids.
  
  
  OBJECTIVE
  To detect whether zileuton directly reduces sebum synthesis.
  
  
  METHODS
  A 40-year-old female with mild disseminated sebaceous gland hyperplasia and seborrhea was treated with zileuton 4 x 600 mg/day over 2 weeks, was followed-up for 6 weeks after discontinuation of zileuton and was re-treated with low-dose isotretinoin 10 mg/2nd day over 5 weeks. Casual skin surface lipids and sebum synthesis were determined.
  
  
  RESULTS
  Under treatment with zileuton increased casual skin surface lipids were normalized and synthesis of facial sebum was decreased. Six weeks after discontinuation of treatment casual skin surface lipids were increased again and synthesis of sebum returned to baseline. Subsequent low-dose isotretinoin treatment led to similar changes of casual skin surface lipids and sebum synthesis with zileuton already after 2 weeks.
  
  
  CONCLUSIONS
  Zileuton directly inhibits sebum synthesis in a transient manner with a potency similar to low-dose isotretinoin at least in our patient.
authors.affiliation: Department of Dermatology, Charité University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany. christos.zouboulis@charite.de
authors.forename: Ch C
authors.initials: ChC
authors.lastname: Zouboulis
authors.forename: A
authors.initials: A
authors.lastname: Saborowski
authors.forename: A
authors.initials: A
authors.lastname: Boschnakow
mesh_terms: D000284:Administration, Oral; D000328:Adult; D012628:Dermatitis, Seborrheic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005145:Face; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016859:Lipoxygenase Inhibitors / Q000008:administration & dosage*; D009333:Neck; D012535:Scalp; D012625:Sebaceous Gland Diseases / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012629:Sebum / Q000187:drug effects / Q000378:metabolism
chemical_list: D016859:Lipoxygenase Inhibitors; C063449:zileuton; D006918:Hydroxyurea